Altana Pharma Ag

Nycomed Gmbh

Takeda Gmbh

Cedona Pharmaceuticals B.v.

Byk Gulden Lomberg Chemische Fabrik Gmbh

Byk Nederland Bv

Khondiron IP B.v.

Altana Pharma B.v.

Rephartox

Khondrion IP B.v.

Geert Jan Sterk

Beate Schmidt

Armin Hatzelmann

Gerhard Grundler

Hans-Peter Kley

Degenhard Marx

Christof Zitt

Anke Heuser

Wiro M P B Menge

Hendrik Timmerman

Jan Bron

Jan F Van Der Werf

Rolf-Peter Hummel

Christian Scheufler

Andrea Wohlsen

Martin Feth

Deborah Ockert

Johannes A M Christiaans

Dieter Flockerzi

Hermann Tenor

Clemens Braun

Imre Schlemminger

Juergen Volz

Margaretha Van Der Mey

Raimund Kuelzer

Pedro Harold Han Hermkens

Ruben Gerardus George Leenders

Steffen Weinbrenner

Josef Stadlwieser

Wolf-R&uuml;diger Ulrich

Raimund Külzer

Jürgen Volz

Richard Hendrik Blaauw

Henk Timmerman

Henk Van Der Goot

Meta E Veerman

Jan Fetze Van Der Werf

Martin P Feth

Wiro MPB Menge

The invention relates to novel compounds that are useful for modulating mitochondrial morphology and/or expression of OXPHOS enzymes and/or cellular ROS. The compounds are derivatives of TroloxrM wherein the carboxylic acid moiety is replaced by an amide moiety and wherein the nitrogen atom of the amide moiety is connected via a linker to a cationic nitrogen atom. The compounds of the invention are formulated into pharmaceutical or cosmetic compositions. The invention further relates to methods wherein the compounds of the invention are used for treating or preventing mitochondrial disorders, conditions associated with mitochondrial dysfunction, including adverse drug effects, and/or neoplastic diseases. The invention also relates to cosmetic methods for treating or delaying further aging of the skin and veterinary applications. 

Chromanyl derivatives for treating mitochondrial disease

The compounds of Formula (I), are novel effective inhibitors of the type 4 phosphodiesterase.

Pyrazolone-derivatives and their use as PDE-4 inhibitors

The compound 1-(2-{4-[3-(3,4-dimethoxyphenyl)-4,4-dimethyl-5-oxo-4,5-dihydro-1H-pyrazol-1-yl]piperidin-1-yl}-2-oxoethyl)pyrrolidine-2,5-dione is a novel effective inhibitor of the type 4 phosphodiesterase useful in the treatment of psoriasis or atopic dermatitis.

Pyrazolone derivatives as PDE4 inhibitors

The compound 1-(2-{4-[3-(3,4-dimethoxyphenyl)-4,4-dimethyl-5-oxo-4,5-dihydro-1H-pyrazol-1-yl]piperidin-1-yl}-2-oxoethyl)pyrrolidine-2,5-dione is a novel effective inhibitor of the type 4 phosphodiesterase.

The compounds of a certain formula 1, in which R1, R7, R8, R9 and n have the meanings as given in the description, are novel effective inhibitors of the type 4 phosphodiesterase.

The compounds of a certain formula (1), in which R1, R2, R3 and R9 have the meanings as given in the description, are novel effective PDE4 inhibitors.

2-(piperidin-4-yl)-4,5-dihydro-2H-pyridazin-3-one derivatives as PDE4 inhibitors

The compounds of formula I in which the given substituents have the meanings as given in the description, are novel effective PDE4 inhibitors.

Phthalazinone-piperidino-derivatives as PDE4 inhibitors

The compounds of formula I in which the substituents have the meanings as indicated in the description, are novel effective PDE4 inhibitors.

Pyrrolidinedione substituted piperidine-phthalazones as PDE4 inhibitors

The compounds of formula I in which R1, R2, R3, R4 and R5 have the meanings as given in the description are PDE4/7 inhibitors.

Phthalazinones

The compounds of formula Iin which R1, R2, R3, A, X, s and R9 have the meanings as given in the description are novel effective PDE4 inhibitors.

Piperazino-derivatives and their use as PDE4 inhibitor

The compounds of a formula I, in which the given substituents have the meanings as given in the description, are novel effective PDE4 inhibitors

The compounds of formula I in which Ar, A, R6, R7, R8 and Arhave the meanings as given in the description are novel effective bronchial therapeutics

Compounds effective as &#x3b2;2-adrenoreceptor agonists as well as PDE4-inhibitors

Growing community of inventors

Utrecht, Netherlands

Geert Jan Sterk